Polyzos, Stergios A.

Year	Article	Times Cited	Times Cited (no self-citations)
2019	Tsourdi E, Makras P, Rachner TD, Polyzos S, Rauner M, Mandanas S, Hofbauer LC, Anastasilakis AD. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone. March 2019;120:44-49.	3	3
2022	Anastasilakis AD, Papachatzopoulos S, Makras P, Gkiomisi A, Nikolakopoulos P, Polyzos SA, Ntenti C, Ballaouri I, Gerou S, Tsachouridou O, Papatheodorou A, Aliazis K, Fermanoglou S, Bisbinas I, Yavropoulou MP. The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. Bone. May 2022;158:116354.	0	0
2021	Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S, Papatheodorou A, Makras P. Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation. Calcif Tiss Int. May 2021;108(5):587-594.	1	1
2017	Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. June 2017;32(6):1291-1296.	23	19
2019	Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res. December 2019;34(12):2220-2228.	14	13

Name	Count	Oldest	Newest
Anastasilakis, Athanasios D.	5	2017	2022
Papapoulos, Socrates E.	1	2019	2019
Lamy, Olivier	1	2017	2017
Hofbauer, Lorenz C.	1	2019	2019
Appelman-Dijkstra, Natasha M.	2	2019	2021
Makras, Polyzois	5	2017	2022
Tsourdi, Elena	1	2019	2019
Aubry-Rozier, Bérengère	1	2017	2017
Rauner, Martina	1	2019	2019